人福医药(600079.SH)：注射用苯磺酸瑞马唑仑增加适应症获得药品注册证书

Core Viewpoint - The company announced that its subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the drug registration certificate for injectable remimazolam from the National Medical Products Administration, marking a significant development in its product portfolio [1] Company Summary - Renfu Pharmaceutical holds an 80% stake in Yichang Renfu, which is involved in the development of the new drug [1] - The injectable remimazolam is a novel benzodiazepine developed in collaboration with the German company PAION, designed as an ultra-short-acting GABAa receptor agonist [1]